Wedbush Reiterates "Outperform" Rating for TScan Therapeutics (NASDAQ:TCRX)

Key Points

• Wedbush has reiterated TScan Therapeutics' "outperform" rating with a price target of $7.00, indicating a potential upside of 324.24% from the current stock price.
• TScan Therapeutics recently reported earnings that surpassed analysts' expectations, with a revenue of $2.17 million compared to a forecast of $1.62 million for the quarter.
• Insider buying activity was noted, with Lynx1 Capital Management purchasing 1,200,000 shares at an average price of $1.20, reflecting a significant increase in their stake in the company.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report)'s stock had its "outperform" rating restated by analysts at Wedbush in a note issued to investors on Tuesday,RTT News reports. They presently have a $7.00 price target on the stock. Wedbush's price target indicates a potential upside of 288.89% from the company's current price. Wedbush also issued estimates for TScan Therapeutics' Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($1.04) EPS, Q1 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.24) EPS, FY2026 earnings at ($0.92) EPS, FY2027 earnings at ($0.97) EPS and FY2028 earnings at ($0.91) EPS.

A number of other research firms have also recently commented on TCRX. Wall Street Zen upgraded TScan Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, July 12th. HC Wainwright dropped their target price on TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $7.80.

TScan Therapeutics Stock Performance

Shares of NASDAQ TCRX traded down $0.01 during mid-day trading on Tuesday, hitting $1.80. The stock had a trading volume of 189,470 shares, compared to its average volume of 266,512. The company has a debt-to-equity ratio of 0.18, a quick ratio of 8.55 and a current ratio of 7.06. The company has a 50 day moving average of $1.67 and a two-hundred day moving average of $1.67. TScan Therapeutics has a twelve month low of $1.02 and a twelve month high of $6.23. The firm has a market cap of $101.86 million, a PE ratio of -1.65 and a beta of 0.99.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.28). TScan Therapeutics had a negative return on equity of 63.33% and a negative net margin of 1,964.88%. The firm had revenue of $3.08 million for the quarter, compared to the consensus estimate of $1.31 million. Research analysts predict that TScan Therapeutics will post -1.12 EPS for the current fiscal year.

Insider Transactions at TScan Therapeutics

In other news, major shareholder Lynx1 Capital Management Lp acquired 1,200,000 shares of the stock in a transaction that occurred on Tuesday, May 20th. The shares were bought at an average cost of $1.20 per share, for a total transaction of $1,440,000.00. Following the acquisition, the insider owned 7,946,141 shares in the company, valued at approximately $9,535,369.20. This represents a 17.79% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.35% of the company's stock.

Institutional Investors Weigh In On TScan Therapeutics

Institutional investors have recently bought and sold shares of the company. Catalyst Funds Management Pty Ltd acquired a new stake in TScan Therapeutics in the 2nd quarter worth about $26,000. Vanguard Personalized Indexing Management LLC acquired a new stake in TScan Therapeutics in the 2nd quarter worth about $29,000. Quadrature Capital Ltd acquired a new stake in TScan Therapeutics in the 2nd quarter worth about $33,000. Boothbay Fund Management LLC boosted its holdings in TScan Therapeutics by 50.0% in the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company's stock worth $35,000 after buying an additional 8,121 shares during the last quarter. Finally, ProShare Advisors LLC acquired a new stake in TScan Therapeutics in the 4th quarter worth about $40,000. 82.83% of the stock is currently owned by institutional investors and hedge funds.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.